Form 4: GoodRx Director Kelly J. Kennedy Receives Significant Equity Grant

GoodRx Holdings, Inc. Director Kelly J. Kennedy was granted 57,050 restricted stock units, aligning her interests with shareholders.

Summary

• GoodRx Holdings, Inc. Director Kelly J. Kennedy acquired 57,050 shares of Class A Common Stock in the form of restricted stock units (RSUs).
• The transaction date for this acquisition was June 3, 2025.
• Each restricted stock unit represents a contingent right to receive one share of Class A common stock.
• The RSUs were granted at a price of $0 per unit, which is typical for equity compensation.
• Following this transaction, Kelly J. Kennedy beneficially owns 111,062 shares of Class A Common Stock.
• The restricted stock units are set to vest in full on the earlier of (i) the one-year anniversary of June 3, 2025, and (ii) the date of the 2026 Annual Meeting of Stockholders, contingent upon continued service through the applicable vesting date.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.

Sentiment

Score: 6

Explanation: The grant of restricted stock units to a director is a routine compensation event that aligns the director's interests with shareholders, indicating standard corporate governance practices. It is generally viewed as a neutral to slightly positive development for corporate alignment.

Positives

• The grant of restricted stock units to a director aligns their financial interests directly with the long-term performance of the company and its shareholders.
• The transaction was conducted under a Rule 10b5-1 plan, indicating a pre-arranged and systematic approach to equity compensation.

Future Outlook

The granted restricted stock units are set to vest in full on the earlier of June 3, 2026, or the date of the 2026 Annual Meeting of Stockholders, subject to continued service, indicating future equity ownership for the director.

Management Comments

• The filing indicates the transaction was made pursuant to a Rule 10b5-1 plan, suggesting a pre-arranged equity compensation strategy for the director.

Industry Context

This equity grant is a standard practice in corporate governance across various industries, including technology and healthcare, aiming to align the interests of directors with those of shareholders and incentivize long-term value creation.

Corporate Governance

Related Party Transactions

• The grant of 57,050 restricted stock units to Kelly J. Kennedy, a director of GoodRx Holdings, Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with those of the shareholders, potentially fostering decisions that enhance long-term shareholder value and demonstrating commitment from leadership.

Next Steps

• Vesting of the 57,050 restricted stock units on the earlier of June 3, 2026, or the 2026 Annual Meeting of Stockholders, contingent on continued service.

Key Dates

Keywords

GoodRx, GDRX, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Grant, Director Compensation, Equity Compensation, Beneficial Ownership